tiprankstipranks
Pressure Biosciences (PBIO)
OTHER OTC:PBIO
US Market

Pressure Biosciences (PBIO) Stock Price & Analysis

55 Followers

PBIO Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.14 - $1.07
Previous Close$0.27
Volume37.26K
Average Volume (3M)98.58K
Market Cap
$6.94M
Enterprise Value$25.70M
Total Cash (Recent Filing)$24.98K
Total Debt (Recent Filing)$18.78M
Price to Earnings (P/E)-0.2
Beta-1.32
May 14, 2024
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.69
Shares Outstanding21,726,433
10 Day Avg. Volume49,929
30 Day Avg. Volume98,578
Standard Deviation0.41
R-Squared0.00016
Alpha0.00054
Financial Highlights & Ratios
Price to Book (P/B)-0.20
Price to Sales (P/S)3.39
Price to Cash Flow (P/CF)-2.00
P/FCF Ratio0.40
Enterprise Value/Market CapN/A
Enterprise Value/Revenue12.82
Enterprise Value/Gross Profit-90.29
Enterprise Value/Ebitda12.39
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

Ownership Overview

2.00%0.00%0.02%97.98%
0.02% Other Institutional Investors
97.98% Public Companies and
Individual Investors

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

PBIO FAQ

What was Pressure Biosciences’s price range in the past 12 months?
Pressure Biosciences lowest stock price was $0.14 and its highest was $1.07 in the past 12 months.
    What is Pressure Biosciences’s market cap?
    Currently, no data Available
    When is Pressure Biosciences’s upcoming earnings report date?
    Pressure Biosciences’s upcoming earnings report date is May 14, 2024 which is in 24 days.
      How were Pressure Biosciences’s earnings last quarter?
      Currently, no data Available
      Is Pressure Biosciences overvalued?
      According to Wall Street analysts Pressure Biosciences’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does Pressure Biosciences pay dividends?
        Pressure Biosciences does not currently pay dividends.
        What is Pressure Biosciences’s EPS estimate?
        Pressure Biosciences’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does Pressure Biosciences have?
        Pressure Biosciences has 25,740,124 shares outstanding.
          What happened to Pressure Biosciences’s price movement after its last earnings report?
          Currently, no data Available
          Which hedge fund is a major shareholder of Pressure Biosciences?
          Currently, no hedge funds are holding shares in PBIO
          ---

          Pressure Biosciences Stock Smart Score

          Company Description

          Pressure Biosciences

          Pressure BioSciences, Inc. is engagedin the development, marketing, and sale of proprietary laboratory instrumentation and associated consumables. Its products includes high pressure barocyclers and barozyme, high pressure generators and accessories, mini ultra-high pressure pump, barocycler and barozyme accessories, microtube accessories for barocyclers and barozyme, high pressure cell disruptors from constant systems, reagent kits, and service contracts. The firm offers its products under the brands Barocycler, PULSE, BioSeq, ProteoSolve, ProteoSolveLRS, Power of PCT, PCT Shredder, HUB440, HUB880, micro- Pestle, PCT-HD, BaroFold, Barozyme and BaroFlex, Strips,The company was founded by Richard T. Schumacher in August 1978 and is headquartered in South Easton, MA.
          ---
          Similar Stocks
          Company
          Price & Change
          Follow
          Organovo Holdings
          Vericel
          Voyager Therapeutics
          Minerva Neurosciences
          Popular Stocks
          ---
          What's Included in PREMIUM?
          Make informed decisions based on Top Analysts' activity
          Know what industry insiders are buying
          Get actionable alerts from top Wall Street Analysts
          Find out before anyone else which stock is going to shoot up
          Get powerful stock screeners & detailed portfolio analysis